Kevin O’Boyle Joins Carlsmed’s Board of Directors

Carlsmed has recruited Kevin O’Boyle to its Board of Directors. He will chair the Audit Committee.
 
O’Boyle previously served as a director of seven publicly traded companies, including Wright Medical Group, GenMark Diagnostics, and Zeltiq. In addition to Carlsmed, he currently serves on the board of Nevro. O’Boyle has more than 20 years of executive management experience and 14 years of experience as a medical device industry boards member.
 
“With his decades of financial governance expertise in the medical technology industry, Kevin is a valuable addition to our Board of Directors,” Carlsmed Chairman/CEO Mike Cordonnier said. “The addition of Kevin to the board is another step forward for our company and comes on the heels of several significant accomplishments.”

---

READ MORE: Carlsmed Raises $52.5M in Series C Financing for Advancing Personalized Spine Surgery

---

 
In August, the company shared clinical demonstrating lower rates of revision surgery for spine procedures using personalized interbody devices. Additionally, as of Oct. 1, spine fusion procedures using its aprevo patient-specific devices will be assigned to the highest level of Medicare Severity-Diagnosis Related Groups (MS-DRG), resulting in more favorable reimbursement on average.
 
“The mounting clinical evidence in support of aprevo patient-specific solutions for spine surgery, combined with favorable reimbursement, points toward a future in which personalized spine surgery is the standard of care and the first choice for patients,” Cordonnier stated.
 
Carlsmed is a Carlsbad, Calif.-based commercial stage technology company and leader of the personalized spine surgery market. aprevo is reportedly the only commercially available custom made anatomically designed interbody for spine fusion surgery.